Rodney Hicks: I am pleased to have been involved in a fantastic international collaboration in a phase I/II trial of Lu-177-satoreotide tetraxetan.

Quoting Rodney Hicks, Professor of Medicine at the University of Melbourne and Monash University, on LinkedIn:

”I am pleased to have been involved in a fantastic international collaboration in a phase I/II trial of Lu-177-satoreotide tetraxetan, a radiolabelled therapeutic somatostatin receptor antagonist, in various neuroendocrine cancers with the results just published in the European Journal of Nuclear Medicine and Molecular Imaging. Many thanks to my former colleagues at Peter Mac and our patients for their involvement. This agent is now being investigated in small cell lung cancer, a disease sorely in need of novel treatment approaches, and I am delighted to remain involved in its further development.”

For the article click here.
Source: Rodney Hicks/LinkedIn